Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)
This study is enrolling participants by invitation only.
Information provided by (Responsible Party):
Mark R. Litzow, Mayo Clinic
First received: March 29, 2012
Last updated: April 25, 2013
Last verified: April 2012
Samples of blood and urine will be analyzed for biomarkers to check their predictivity of Graft-versus-Host Disease (GVHD) outcomes.
Blood Stem Cell Transplant Failure
||Observational Model: Cohort
Time Perspective: Prospective
||Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD).
Primary Outcome Measures:
- Diagnosis of severe acute GVHD [ Time Frame: 2 months ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||March 2014 (Final data collection date for primary outcome measure)
Post allogeneic SCT patients
Patients who have undergone an allogeneic stem cell transplant.
To determine if serum biomarkers of inflammation correlate with onset and severity of acute GVHD, particularly GVHD of the gut.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients who have undergone an allogeneic stem cell transplant being followed for post transplant care.
- 18 years old or older patients
- Undergoing allogeneic stem cell transplant
Please refer to this study by its ClinicalTrials.gov identifier: NCT01569373
|Rochester, Minnesota, United States, 55905 |
||Mark Litzow, MD
No publications provided
||Mark R. Litzow, MD, Mayo Clinic
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 29, 2012
||April 25, 2013
||United States: Institutional Review Board
Keywords provided by Mayo Clinic:
Allogeneic stem cell transplant
Graft versus Host Disease
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 11, 2013
Graft vs Host Disease
Immune System Diseases